Lv71
5000 积分 2023-10-08 加入
Allergen immunotherapy: past, present and future
9天前
已完结
疫苗运输与储存管理在基层工作中的经验探讨
13天前
已完结
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
25天前
已完结
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)
1个月前
已完结
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
1个月前
已完结
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
1个月前
已完结
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
1个月前
已完结
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
3个月前
已完结
P-361 Busulfan Plus Melphalan versus Melphalan Alone as Conditioning Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Long-Term Follow Up of a Randomized Phase III Trial
3个月前
已关闭
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
3个月前
已完结
皖公网安备34019202002308
